JAHEN(SZ:300955)2022-08-26 16:00Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥459.87 million, a decrease of 10.57% compared to ¥514.25 million in the same period last year[20]. - The net profit attributable to shareholders of the listed company was approximately ¥26.53 million, down 28.67% from ¥37.19 million in the previous year[20]. - The net cash flow from operating activities was approximately ¥25.89 million, representing a decline of 48.05% compared to ¥49.84 million in the same period last year[20]. - Basic earnings per share decreased by 38.10% to ¥0.26 from ¥0.42 in the previous year[20]. - Total assets at the end of the reporting period were approximately ¥1.34 billion, a decrease of 1.13% from ¥1.36 billion at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were approximately ¥945.32 million, down 1.23% from ¥957.07 million at the end of the previous year[20]. - The weighted average return on net assets was 2.73%, a decrease of 2.37% compared to 5.10% in the previous year[20]. - The company reported a total non-operating income of 1,331,783.79, after deducting the income tax impact of 315,460.23[25]. - The company reported a total of ¥31,060,795.66 in other receivables as of June 30, 2022, slightly down from ¥32,414,621.34[151]. - The company reported a net profit margin of approximately 5.9% for the first half of 2022, down from 7.5% in the same period of 2021[158]. Market and Industry Insights - The cosmetics market in China has shown significant growth, with retail sales increasing from 204.94 billion to 402.6 billion from 2015 to 2021, despite a 2.5% decline in the first half of 2022 due to external pressures[36]. - The company is positioned to benefit from the increasing demand for cosmetics production capacity, driven by both international brands localizing operations and the resurgence of domestic brands[37]. - The cosmetic industry is experiencing increased regulatory scrutiny, which is expected to raise industry standards and eliminate weaker competitors[40]. - The company faces risks including market demand fluctuations, high customer concentration, and raw material price volatility[3]. Research and Development - The company emphasizes continuous investment in R&D for product formulation and process optimization, aiming to enhance its market influence and customer base[34]. - The company is focusing on R&D in high-efficacy product formulations, including scalp care and skin barrier repair, to enhance product development efficiency[43]. - The company has added 9 new patents from January to July 2022, including 7 utility model patents and 2 invention patents[43]. - The company's R&D investment was ¥9,956,654.90, down 5.86% from ¥10,576,850.17 in the previous year[52]. Operational Strategies - The company has established long-term stable relationships with suppliers to ensure a steady supply of raw materials, which helps control procurement costs and reduce operational risks[29]. - The company operates under an OEM model for daily chemical products, with a focus on customer-specific production plans and quality control[30]. - The company is enhancing its quality control systems and production efficiency through lean management practices[42]. - The company aims to optimize its supply chain and production scheduling to reduce inventory levels and associated risks as it expands its operational scale[93]. Financial Management and Investments - The total investment during the reporting period was CNY 102,127,407.14, a significant decrease of 61.08% compared to CNY 262,374,785.38 in the same period last year[65]. - The company has ongoing projects with a total investment of CNY 65,287,818.54, with actual investment reaching CNY 306,697,818.45[68]. - The company has invested 6.6 million CNY in entrusted financial management products, with no overdue amounts reported[82]. - The company has identified risks related to the feasibility of its fundraising investment projects, which may not meet expected returns if market conditions change unfavorably[94]. Shareholder and Corporate Governance - The company’s total share capital is 100.8 million shares, with 55.49% held by foreign investors after the release of 19.66 million shares from lock-up[131][132]. - The company’s controlling shareholders and actual controllers maintained good integrity, with no significant debts due that were unpaid[111]. - The company did not engage in any asset or equity acquisitions or sales during the reporting period, nor did it have any related party transactions[112][113]. - The company has not reported any major changes in the feasibility of its investment projects[75]. Social Responsibility and Compliance - The company actively fulfilled its corporate social responsibilities, with a public donation expenditure of approximately CNY 260,000 for public welfare in the first half of 2022[103]. - The company maintained a strong focus on environmental protection, achieving ISO 14001 certification and ensuring that pollutant discharge met standards, with no environmental pollution incidents reported during the reporting period[103]. - The company has established a pandemic prevention working group and donated epidemic prevention materials as part of its social responsibility efforts[103]. - The company reported no major safety incidents during the reporting period, adhering to safety production guidelines and conducting regular safety training and assessments[103].